Nothing Special   »   [go: up one dir, main page]

CR20110154A - Anticuerpos biespecíficos anti-egfr/anti-igf-1r - Google Patents

Anticuerpos biespecíficos anti-egfr/anti-igf-1r

Info

Publication number
CR20110154A
CR20110154A CR20110154A CR20110154A CR20110154A CR 20110154 A CR20110154 A CR 20110154A CR 20110154 A CR20110154 A CR 20110154A CR 20110154 A CR20110154 A CR 20110154A CR 20110154 A CR20110154 A CR 20110154A
Authority
CR
Costa Rica
Prior art keywords
antibodies
igf
egfr
biespectific
production
Prior art date
Application number
CR20110154A
Other languages
English (en)
Inventor
Ulrich Brinkmann
Rebecca Croasdale
Wilma Lau
Christian Gerdes
Eike Hoffmann
Christian Klein
Klaus-Peter Kuenkele
Wolfgang Schaefer
Jan Olaf Stracke
Pablo Umana
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CR20110154A publication Critical patent/CR20110154A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención esta relacionada con anticuerpos biespecíficos frente a EGFR y frente a IGF-1R, métodos para su producción, composiciones farmacéuticas que contienen dichos anticuerpos y usos de los mismos.
CR20110154A 2008-09-26 2011-03-22 Anticuerpos biespecíficos anti-egfr/anti-igf-1r CR20110154A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08016952 2008-09-26

Publications (1)

Publication Number Publication Date
CR20110154A true CR20110154A (es) 2011-05-12

Family

ID=40352483

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110154A CR20110154A (es) 2008-09-26 2011-03-22 Anticuerpos biespecíficos anti-egfr/anti-igf-1r

Country Status (1)

Country Link
CR (1) CR20110154A (es)

Similar Documents

Publication Publication Date Title
CO6362023A2 (es) Anticuerpos biespecificos anti-egfr/ anti-igf-1r
ECSP11011387A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
AR076194A1 (es) Anticuerpos biespecificos anti-erbb-2/anti-c-met
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
CO7081144A2 (es) Anticuerpos biespecíficos contra tweak humana e il17 humana y usos de los mismos
ECSP12011701A (es) Anticuerpos anti-cdcp1 humanizados
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
ECSP11010969A (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
BR112015006824A2 (pt) anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
UY31611A1 (es) Compuestos que comprenden un grupo ciclobutoxi
CR11623A (es) Compuestos
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
ECSP14004976A (es) Anticuerpos anti-il-36r
UY33310A (es) Sintesis estereoselectiva de activos que contienen fosforo
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
CR20160147A (es) Formulaciones de anticuerpos
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
ECSP12012221A (es) Anticuerpos anti-cd40
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CL2016001592A1 (es) Anticuerpos y métodos de uso
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
UY31871A (es) Compuestos que comprenden un grupo ciclobutoxi